✅ Product Overview

• GLP-1 receptor activation: Enhances satiety signaling, reduces appetite,
  slows gastric emptying, and supports glucose-dependent insulin secretion.
• GIP receptor activation: Improves insulin sensitivity and amplifies
  metabolic efficiency, potentially mitigating some GLP-1–related GI limitations.
• Glucagon receptor activation: Increases energy expenditure, promotes
  hepatic fat oxidation, and supports basal metabolic rate—one of the key differentiators
  of retatrutide versus GLP-1/GIP-only compounds.
• Net effect: Simultaneous appetite suppression and increased
  caloric expenditure—targeting both sides of the energy balance equation.

Retatrutide is typically evaluated using a gradual once-weekly titration model
to improve tolerability and minimize gastrointestinal side effects.
The following represents a commonly referenced research-based titration framework.

1. Weeks 1–4: Very low introductory dose (often sub-therapeutic)
2. Weeks 5–8: Incremental increase as tolerance improves
3. Ongoing: Stepwise increases every 3–4 weeks as needed
4. Advanced phase: Higher maintenance ranges used only after full adaptation

• Protein-priority nutrition: Supports lean mass preservation during rapid fat loss.
• Smaller meal volumes: Helps reduce nausea and reflux due to delayed gastric emptying.
• Moderate fat intake: Excessive fats near injection days may worsen GI symptoms.
• Hydration & electrolytes: Critical when appetite is suppressed.
• Resistance training: 2–4× weekly to maintain metabolic rate and muscle tissue.
• Daily movement: Enhances glucagon-driven fat oxidation benefits.

🚫 Do NOT use if you have:

• Personal or family history of medullary thyroid carcinoma (MTC)
• MEN-2 (Multiple Endocrine Neoplasia type 2)
• Known hypersensitivity to incretin-based peptides

⚠️ Use extreme caution with:

• History of pancreatitis
• Severe gastrointestinal disorders
• Gallbladder disease
• Advanced kidney disease or dehydration risk
• Pregnancy or breastfeeding

• Other GLP-1, GIP, or glucagon receptor agonists
• Insulin or insulin secretagogues (hypoglycemia risk)
• Oral medications with narrow absorption windows
• Oral contraceptives (effectiveness may be reduced during titration)

• Nausea
• Reduced appetite
• Diarrhea or constipation
• Fatigue during early titration
• Injection-site irritation